Search

Your search keyword '"Zaiss, Matthias"' showing total 44 results
Start Over Author "Zaiss, Matthias"
44 results on '"Zaiss, Matthias"'

2. Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial

Author

Mai, Elias K., Bertsch, Uta, Pozek, Ema, Fenk, Roland, Besemer, Britta, Hanoun, Christine, Schroers, Roland, von Metzler, Ivana, Hänel, Mathias, Mann, Christoph, Leypoldt, Lisa B., Heilmeier, Bernhard, Huhn, Stefanie, Vogel, Sabine K., Hundemer, Michael, Scheid, Christof, Blau, Igor W., Luntz, Steffen, Weinhold, Niels, Tichy, Diana, Holderried, Tobias A.W., Trautmann-Grill, Karolin, Gezer, Deniz, Klaiber-Hakimi, Maika, Müller, Martin, Shumilov, Evgenii, Knauf, Wolfgang, Michel, Christian S., Geer, Thomas, Riesenberg, Hendrik, Lutz, Christoph, Raab, Marc S., Benner, Axel, Hoffmann, Martin, Weisel, Katja C., Salwender, Hans J., Goldschmidt, Hartmut, Ahlborn, Miriam, Behringer, Joachim, Bernhard, Helga, Besemer, Britta, Bittenbring, Jörg, Blau, Igor Wolfgang, Bolling, Claus, Boquoi, Amelie, Debatin, Daniel, Egerer, Gerlinde, Fenk, Roland, Ferstl, Barbara, Fronhoffs, Stefan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Hoffmann, Martin, Holderried, Tobias A.W., Hopfer, Olaf, Janjetovic, Snjezana, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Kraemer, Doris Maria, Kropff, Martin, La Rosée, Paul, Mahlberg, Rolf, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Michel, Christian, Müller, Martin, Pönisch, Wolfram, Reimer, Peter, Riechel, Claudia, Ringhoffer, Mark, Rummel, Mathias, Runde, Volker, Salwender, Hans Jürgen, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schöndube, Daniel, Schroers, Roland, Schütte, Hans-Joachim, Shumilov, Evgenii, Staib, Peter, Strumberg, Dirk, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Verbeek, Walter, Weide, Rudolf, Weidmann, Eckhart, Weisel, Katja, de Wit, Maike, Bernhardt, Christiane, Fietz, Thomas, Grassinger, Jochen, Köchling, Georg, Neise, Michael, Schmitt, Stefan, Steiniger, Heike, Tschechne, Barbara, Whitlock, Bettina, Zaiß, Matthias, and Ziske, Carsten

Published
2024
Full Text
View/download PDF

3. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Author

Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, de Wit, Maike, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Eberhardt, Wilfried, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Griesinger, Frank, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig Carla, Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hummel, Horst-Dieter, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kaiser, Ulrich, Kamal, Haytham, Kambartel, Kato, Kern, Jens, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Müller, Lothar, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schäfer, Harald, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt Peter, Florian, Sebastian, Martin, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Uhlig, Jens, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, Zeth, Matthias, Eberhardt, Wilfried E.E., Brueckl, Wolfgang M., Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Hipper, Annette, Groth, Annika, Weichert, Wilko, and Thomas, Michael

Published
2024
Full Text
View/download PDF

4. The INFINITY study protocol: a retrospective cohort study on decision making and clinical impact of biomarker-driven precision oncology in routine clinical practice

Author

Martens, Uwe M., Schröder, Jan, Bengsch, Fee, Sellmann, Ludger, Busies, Sabine, Frank-Gleich, Stefanie, Zaiss, Matthias, Decker, Thomas, Schneeweiss, Andreas, Schuler, Martin, Grebhardt, Sina, Zacharias, Stefan, Marschner, Norbert, Kasenda, Benjamin, Potthoff, Karin, and Vannier, Corinne

Published
2023
Full Text
View/download PDF

5. PRECYCLE: multicenter, randomized phase IV intergroup trial to evaluate the impact of eHealth-based patient-reported outcome (PRO) assessment on quality of life in patients with hormone receptor positive, HER2 negative locally advanced or metastatic breast cancer treated with palbociclib and an aromatase inhibitor or palbociclib and fulvestrant

Author

Degenhardt, Tom, Fasching, Peter A., Lüftner, Diana, Müller, Volkmar, Thomssen, Christoph, Schem, Christian, Witzel, Isabell, Decker, Thomas, Tesch, Hans, Kümmel, Sherko, Uleer, Christoph, Wuerstlein, Rachel, Hoffmann, Oliver, Warm, Mathias, Marschner, Norbert, Schinköthe, Timo, Kates, Ronald E., Schumacher, Johannes, Otremba, Burkhard, Zaiss, Matthias, Harbeck, Nadia, and Schmidt, Marcus

Published
2023
Full Text
View/download PDF

6. Significantly longer time to deterioration of quality of life due to CANKADO PRO-React eHealth support in HR+ HER2− metastatic breast cancer patients receiving palbociclib and endocrine therapy: primary outcome analysis of the multicenter randomized AGO-B WSG PreCycle trial

Author

Kieback, Dirk Günter, van Mackelenbergh, Marion Tina, Hielscher, Carsten, Ugur, Mustafa Celalettin, Uleer, Christoph, Zahn, Mark-Oliver, Meyer, Ralf, Kraudelt, Susanne, Stefek, Andrea, Pink, Daniel, Just, Marianne, Kolberg, Hans-Christian, Fehm, Tanja, Malter, Wolfram, Warm, Mathias, Forstbauer, Helmut, Behringer, Dirk, Wortmann, Anke, Rom, Joachim, Lehnert, Antje, Ackermann, Sven, Guth, Dagmar, Simon, Eike, Dünnebacke, Jan, Hönig, Arnd, Ehscheidt, Peter, Gnauert, Karsten, Kühn, Thorsten, von Abel, Ekkehard, Hartkopf, Andreas, Karck, Ulrich, Negwer, Martina, Wacker, Jürgen, Welslau, Manfred, Sagasser, Jaqueline, Heinrichm, Bernhard, Brucker, Cosima, Stauder, Heribert, Gröll, Isolde, Felberbaum, Ricardo, Popovic, Milos, Baerens, Dirk-Toralf, Söling, Ulrike, Zaiss, Matthias, Rauh, Jaqueline, Fietz, Thomas, Schröder, Jan, Voß, Hermann, Mohm, Johannes, Neef, Ute, Rieger, Lorenz, Distelrath, Andrea, Nusch, Arnd, Schmidt, Burkhard, Lüdtke-Heckenkamp, Kerstin, Berghorn, Michael, Busch, Steffi, Schock, Caroline, Metz, Michael, Lorenz, Andreas, Uhlig, Jens, Otremba, Burkhard, Harbeck, N., Fasching, P.A., Wuerstlein, R., Degenhardt, T., Lüftner, D., Kates, R.E., Schumacher, J., Räth, P., Hoffmann, O., Lorenz, R., Decker, T., Reinisch, M., Göhler, T., Staib, P., Gluz, O., Schinköthe, T., and Schmidt, M.

Published
2023
Full Text
View/download PDF

8. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Asemissen, Anne M, Behringer, Joachim, Bernhard, Helga, Bernhardt, Christiane, Bertsch, Uta, Besemer, Britta, Blau, Igor W, Bolling, Claus, Debatin, Daniel, Dingeldein, Gerrit, Dürig, Jan, Fenk, Roland, Ferstl, Barbara, Fest, Claudia, Fronhoffs, Stefan, Fuhrmann, Stephan, Gaska, Tobias, Geer, Thomas, Gezer, Deniz, Goldschmidt, Hartmut, Görner, Martin, Graeven, Ullrich, Grassinger, Jochen, Hänel, Mathias, Heilmeier, Bernhard, Heinsch, Michael, Held, Gerhard, Hoffmann, Martin, Holderried, Tobias A W, Hopfer, Olaf, Huhn, Stefanie, Immenschuh, Peter, Kaddu-Mulindwa, Dominic, Khandanpour, Cyrus, Klaiber-Hakimi, Maika, Klausmann, Martine, Klein, Stefan, Knauf, Wolfgang, Ko, Yon-Dschun, Köchling, Georg, Koenigsmann, Michael, Kostrewa, Philippe, Kraemer, Doris Maria, Kremers, Stephan, Kriegsmann, Katharina, Kropff, Martin, La Rosée, Paul, Luntz, Steffen P, Mahlberg, Rolf, Mai, Elias K, Mann, Christoph, Martens, Uwe, von Metzler, Ivana, Müller, Martin, Munder, Markus, Neise, Michael, Nievergall, Eva, Nückel, Holger, Pönisch, Wolfram, Procaccianti, Maria, Raab, Marc S, Rafiyan, Mohammed R, Reimer, Peter, Riecke, Armin, Riesenberg, Hendrik, Rummel, Mathias, Runde, Volker, Salwender, Hans J, Schaich, Markus, Scheid, Christoph, Schmidt-Hieber, Martin, Schmitt, Stefan, Schöndube, Daniel, Schroers, Roland, Schwarzer, Andreas, Staib, Peter, Steiniger, Heike, Sturmberg, Dirk, Thomalla, Jörg, Tichy, Diana, Tischler, Hans-Joachim, Trautmann-Grill, Karolin, Trummer, Arne, Tschechne, Barbara, Verbeek, Walter, Weinhold, Niels, Weisel, Katja C, Whitlock, Bettina, de Wit, Maike, Zaiß, Matthias, Ziske, Carsten, and Scheid, Christof

Published
2022
Full Text
View/download PDF

9. Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV.

Author

Harbeck, Nadia, primary, Braun, Michael, additional, Gluz, Oleg, additional, Schmid, Peter, additional, Graeser, Monika Karla, additional, Hartkopf, Andreas D., additional, Hoffmann, Oliver, additional, Kostara, Athina, additional, Polata, Silke, additional, Volmer, Lea Louise, additional, von Schumann, Raquel, additional, Wetzig, Sarah, additional, Wiebe, Stefanie, additional, Zaiss, Matthias R., additional, Fischer, Lotta Ada, additional, Scheffen, Iris, additional, Christgen, Matthias, additional, Kreipe, Hans Heinrich, additional, Nitz, Ulrike, additional, and Kuemmel, Sherko, additional

Published
2024
Full Text
View/download PDF

10. Neratinib as extended adjuvant treatment of HER2-positive/HR-positive early breast cancer patients in Germany, Austria and Switzerland: interim results of the prospective, observational ELEANOR study

Author

Harbeck, Nadia, primary, Wrobel, Denise, additional, Zaiss, Matthias, additional, Terhaag, Jürgen, additional, Guth, Dagmar, additional, Distelrath, Andrea, additional, Zahn, Mark-Oliver, additional, Würstlein, Rachel, additional, Lorenz, Andreas, additional, Bartsch, Rupert, additional, Breitenstein, Urs, additional, Schwitter, Michael, additional, Balic, Marija, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rinnerthaler, Gabriel, additional, Schmidt, Marcus, additional, Zaman, Khalil, additional, Schinköthe, Timo, additional, Resch, Anna, additional, Valenti, Roberta, additional, and Lueftner, Diana, additional

Published
2023
Full Text
View/download PDF

11. Final Results from RIBBIT: A Randomized Phase III Study to Evaluate Efficacy and Quality of Life in Patients with Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Receiving Ribociclib in Combination with Endocrine Therapy or Chemotherapy with or without Bevacizumab in the First-Line Setting

Author

Decker, Thomas, Zaiss, Matthias, Klein, Dunja, Hahn, Antje, Hagen, Volker, La Rosée, Paul, Liersch, Rüdiger, Wolff, Thomas, Niemeier, Beate, Hillebrand, Larissa E., Lennartz, Carolin, Chiabudini, Marco, Bengsch, Fee, Indorf, Martin, and Marschner, Norbert

Subjects
BREAST tumor diagnosis, THERAPEUTIC use of antineoplastic agents, CANCER patient psychology, DRUG efficacy, CONFIDENCE intervals, PROTEIN kinase inhibitors, CANCER chemotherapy, METASTASIS, TREATMENT effectiveness, RANDOMIZED controlled trials, QUALITY of life, DESCRIPTIVE statistics, RESEARCH funding, QUESTIONNAIRES, PROGRESSION-free survival, BREAST tumors, OVERALL survival, LONGITUDINAL method, EVALUATION
Abstract

Background: We investigated the efficacy and health-related quality of life (HRQoL) in patients receiving either ribociclib plus endocrine therapy (ET) or chemotherapy with/without bevacizumab as first-line treatment of metastatic hormone receptor (HR)-positive, HER2-negative breast cancer (BC). Patients and Methods: In this randomized, phase III study (RIBBIT), 38 patients diagnosed with metastatic HR-positive, HER2-negative BC with presence of visceral metastases recruited between May 2018 and December 2020 were randomly assigned in a 1:1 ratio to either arm A (ribociclib + ET) or arm B (chemotherapy with/without bevacizumab) at 12 sites in Germany. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall response rate (ORR), overall survival (OS), patient-reported HRQoL, and frequency and type of adverse events. During study conduction, the recruitment rate was persistently and considerably lower than originally expected. Therefore, the recruitment was ended prematurely. The study was initially designed to enroll and randomize 158 patients. Results: Median [95% CI] PFS was 27.3 months [19.1 – NA, parameter not estimable] in arm A and 15.8 months [8.2 – NA] in arm B. Complete responses were achieved only in arm A (n = 2, 10.5%). The ORR [95% CI] between arm A (57.9% [33.5–79.7]) and arm B (52.6% [28.9–75.6]) was comparable. Median OS [95% CI] was not reached in arm A, while in arm B median OS was 28.4 months [25.0 – NA]. Patients in arm A reported less burden by side-effects. No new safety signals emerged. Conclusion: Treatment of patients with visceral metastatic HR-positive, HER2-negative BC with ribociclib in combination with ET showed a tendency toward a more favorable clinical outcome. Despite small numbers of patients and sites, this head-to-head comparison with chemotherapy supports the use of ribociclib with ET in patients with visceral metastasis at risk of fast disease progression. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Neratinib as Extended Adjuvant Treatment of HER2-Positive/HR-Positive Early Breast Cancer Patients in Germany, Austria, and Switzerland: Interim Results of the Prospective, Observational ELEANOR Study.

Author

Harbeck, Nadia, Wrobel, Denise, Zaiss, Matthias, Terhaag, Jürgen, Guth, Dagmar, Distelrath, Andrea, Zahn, Mark-Oliver, Würstlein, Rachel, Lorenz, Andreas, Bartsch, Rupert, Breitenstein, Urs, Schwitter, Michael, Balic, Marija, Jackisch, Christian, Müller, Volkmar, Rinnerthaler, Gabriel, Schmidt, Marcus, Zaman, Khalil, Schinköthe, Timo, and Resch, Anna

Subjects
THERAPEUTIC use of antineoplastic agents, ADJUVANT chemotherapy, DRUG efficacy, RESEARCH, CLINICAL trials, EPIDERMAL growth factor receptors, ANTINEOPLASTIC agents, PROTEIN-tyrosine kinase inhibitors, DRUGS, DESCRIPTIVE statistics, RESEARCH funding, PATIENT compliance, HORMONE receptor positive breast cancer, BREAST tumors, LONGITUDINAL method, EVALUATION
Abstract

Introduction: Prognosis of patients diagnosed with HER2+ early breast cancer (eBC) has substantially improved, but distant recurrences impacting quality of life and survival still occur. One treatment option for extended adjuvant treatment of patients with HER2+/HR+ eBC is neratinib, available in Europe for patients who completed adjuvant trastuzumab-based therapy within 1 year. The ELEANOR study is investigating the real-world use of neratinib in Germany, Austria, and Switzerland. Results from an interim analysis of the first 200 patients observed for ≥3 months are reported. Methods: The primary objective of this prospective, multicenter, observational study is to assess patient adherence to neratinib (defined as the percentage of patients taking neratinib on ≥75% prescribed days). Secondary objectives are patient characteristics and treatment outcomes. Results: At cut-off (May 2, 2022), a total of 202 patients had been observed for ≥3 months, with neratinib treatment documented for 187 patients (median age: 53.0 years; 67.9% at increased risk of disease recurrence). In total, 151 (80.7%) patients had received prior neoadjuvant treatment; of these, 82 (54.3%) patients achieved a pathologically complete response. Neratinib was initiated at a median 3.6 months after trastuzumab-based treatment, with 36.4% starting at a dose <240 mg/day. Treatment is ongoing for 46.0% of patients, with median treatment duration of 11.2 (interquartile range 0.9–12.0) months. Diarrhea was the most common adverse event (78.6% any grade, 20.3% grade ≥3); pharmacologic prophylaxis was used in 85.6% of patients. Conclusions: The pattern of anti-HER2 pretreatment observed reflected the current treatment for HER2+/HR+ eBC in Germany, Austria, and Switzerland. These interim results suggest that neratinib as an extended adjuvant is a feasible option after various anti-HER2 pretreatments and that its tolerability can be managed and improved with proactive diarrhea management. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Abstract P2-01-01: Interim analysis (n=200) from ELEANOR: a multi-national, prospective, non-interventional study among patients with HER2+ and HR+ early breast cancer treated with extended adjuvant neratinib in the clinical routine

Author

Bartsch, Rupert, primary, Harbeck, Nadia, additional, Wrobel, Denise, additional, Zaiss, Matthias, additional, Terhaag, Jürgen, additional, Guth, Dagmar, additional, Distelrath, Andrea, additional, Wuerstlein, Rachel, additional, Zahn, Mark-Oliver, additional, Lüftner, Diana, additional, Schwitter, Michael, additional, Balic, Marija, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rinnerthaler, Gabriel, additional, Schmidt, Marcus, additional, Zaman, Khalil, additional, Schinköthe, Timo, additional, Resch, Anna, additional, and Breitenstein, Urs, additional

Published
2023
Full Text
View/download PDF

14. Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial

Author

Goldschmidt, Hartmut, primary, Mai, Elias K, additional, Bertsch, Uta, additional, Fenk, Roland, additional, Nievergall, Eva, additional, Tichy, Diana, additional, Besemer, Britta, additional, Dürig, Jan, additional, Schroers, Roland, additional, von Metzler, Ivana, additional, Hänel, Mathias, additional, Mann, Christoph, additional, Asemissen, Anne M, additional, Heilmeier, Bernhard, additional, Weinhold, Niels, additional, Huhn, Stefanie, additional, Kriegsmann, Katharina, additional, Luntz, Steffen P, additional, Holderried, Tobias A W, additional, Trautmann-Grill, Karolin, additional, Gezer, Deniz, additional, Klaiber-Hakimi, Maika, additional, Müller, Martin, additional, Khandanpour, Cyrus, additional, Knauf, Wolfgang, additional, Scheid, Christof, additional, Munder, Markus, additional, Geer, Thomas, additional, Riesenberg, Hendrik, additional, Thomalla, Jörg, additional, Hoffmann, Martin, additional, Raab, Marc S, additional, Salwender, Hans J, additional, Weisel, Katja C, additional, Behringer, Joachim, additional, Bernhard, Helga, additional, Bernhardt, Christiane, additional, Blau, Igor W, additional, Bolling, Claus, additional, Debatin, Daniel, additional, Dingeldein, Gerrit, additional, Ferstl, Barbara, additional, Fest, Claudia, additional, Fronhoffs, Stefan, additional, Fuhrmann, Stephan, additional, Gaska, Tobias, additional, Goldschmidt, Hartmut, additional, Görner, Martin, additional, Graeven, Ullrich, additional, Grassinger, Jochen, additional, Heinsch, Michael, additional, Held, Gerhard, additional, Hopfer, Olaf, additional, Immenschuh, Peter, additional, Kaddu-Mulindwa, Dominic, additional, Klausmann, Martine, additional, Klein, Stefan, additional, Ko, Yon-Dschun, additional, Köchling, Georg, additional, Koenigsmann, Michael, additional, Kostrewa, Philippe, additional, Kraemer, Doris Maria, additional, Kremers, Stephan, additional, Kropff, Martin, additional, La Rosée, Paul, additional, Mahlberg, Rolf, additional, Martens, Uwe, additional, Neise, Michael, additional, Nückel, Holger, additional, Pönisch, Wolfram, additional, Procaccianti, Maria, additional, Rafiyan, Mohammed R, additional, Reimer, Peter, additional, Riecke, Armin, additional, Rummel, Mathias, additional, Runde, Volker, additional, Schaich, Markus, additional, Scheid, Christoph, additional, Schmidt-Hieber, Martin, additional, Schmitt, Stefan, additional, Schöndube, Daniel, additional, Schwarzer, Andreas, additional, Staib, Peter, additional, Steiniger, Heike, additional, Sturmberg, Dirk, additional, Tischler, Hans-Joachim, additional, Trummer, Arne, additional, Tschechne, Barbara, additional, Verbeek, Walter, additional, Whitlock, Bettina, additional, de Wit, Maike, additional, Zaiß, Matthias, additional, and Ziske, Carsten, additional

Published
2022
Full Text
View/download PDF

15. Prognostic factors in non-small-cell lung cancer: insights from the German crisp registry

Author

Griesinger, Frank, Hummel, Horst-Dieter, Schäfer, Harald, de Wit, Maike, Kaiser, Ulrich, Kern, Jens, Jänicke, Martina, Spring, Lisa, Zacharias, Stefan, Kaiser-Osterhues, Anja, Groth, Annika, Hipper, Annette, Zaun, Gregor, Müller, Lothar, Uhlig, Jens, Thomas, Michael, Sebastian, Martin, Eberhardt, Wilfried, Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig, Carla Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kamal, Haytham, Kambartel, Kato, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt, Peter Florian, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, and Zeth, Matthias

Subjects
Pulmonary and Respiratory Medicine, Medizin
Abstract

IntroductionUnderstanding prognosis, especially long-term outcome, in advanced nonsmall cell lung cancer (NSCLC) is crucial to inform patients, guide treatment and plan supportive and palliative care.MethodsPrognostic factors influencing overall survival (OS) and progression-free survival (PFS) in 2082 patients with wild-type (WT)-NSCLC (629 M1a, 249 M1b, 1204 M1c) are reported. Patients were included in the prospective German CRISP registry recruiting in >150 centres. Analysis for pre-therapeutic factors was based on results from Cox proportional hazard models.ResultsCurrent M-descriptors of the Union for International Cancer Control-8 staging system were validated: M1a and M1b patients had significantly longer median time to events compared to M1c (OS/PFS 16.4/7.2 months, 17.8/6.7 months and 10.9/5.4 months, respectively). OS and PFS were influenced by number and location of metastatic organ systems. M1c and four or more metastatic organs involved had shorter OS and PFS than M1c with one to three organs (OS hazard ratio (HR) 1.69, pConclusionIn this large observational dataset, we further defined factors for outcome in WT-NSCLC, including increased number of involved metastatic organ systems and liver metastases, as those with overall poorer prognosis and reduced survival chance.

Published
2022

16. Abstract P2-13-30: First interim analysis from ELEANOR: A multi-national, prospective, non-interventional study (NIS) in patients with human epidermal growth factor receptor positive (HER2+) early breast cancer observing real-life extended adjuvant treatment with neratinib

Author

Lüftner, Diana, primary, Bartsch, Rupert, additional, Breitenstein, Urs, additional, Balic, Marija, additional, Jackisch, Christian, additional, Müller, Volkmar, additional, Rinnerthaler, Gabriel, additional, Schmidt, Marcus, additional, Schwitter, Michael, additional, Zaman, Khalil, additional, Wrobel, Denise, additional, Guth, Dagmar, additional, Terhaag, Jürgen, additional, Zaiss, Matthias, additional, Schinköthe, Timo, additional, and Harbeck, Nadia, additional

Published
2022
Full Text
View/download PDF

17. NADIR: A Non-Interventional Study on the Prophylaxis of Chemotherapy-Induced Neutropenia Using Lipegfilgrastim - First Interim Analysis

Author

Kurbacher, Christian M., Fietz, Thomas, Diel, Ingo J., Egert, Matthias, Hurtz, Hans-Jürgen, Lück, Andreas, Weide, Rudolf, Salat, Christoph, Wolff, Thomas, Zaiss, Matthias, Klare, Peter, Losem, Christoph, Illmer, Thomas, Weienborn, Georg, Steffens, Claus-Christoph, Schulze, Matthias, Tesch, Hans, Oskay-Oezcelik, Gülten, Teichmann, Beate, Harde, Johanna, and Scheuerlein, Robert Willy

Published
2015
Full Text
View/download PDF

19. PRECYCLE: Multicenter, Randomized Phase IV Intergroup Trial to Evaluate the Impact of E Health-Based Patient Reported Outcome (PRO) Assessment on Quality of Life in Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Treated with Palbociclib and an Aromatase Inhibitor- or Palbociclib and Fulvestrant

Author

Degenhardt, Tom, primary, Fasching, Peter A., additional, Lüftner, Diana, additional, Müller, Volkmar, additional, Thomssen, Christoph, additional, Schem, Christian, additional, Witzel, Isabell, additional, Decker, Thomas, additional, Tesch, Hans, additional, Kümmel, Sherko, additional, Uleer, Christoph, additional, Wuerstlein, Rachel, additional, Hoffmann, Oliver, additional, Schumacher, Johannes, additional, Warm, Mathias, additional, Marschner, Norbert, additional, Schinköthe, Timo, additional, Kates, Ronald E., additional, Otremba, Burkhard, additional, Zaiss, Matthias, additional, Harbeck, Nadia, additional, and Schmidt, Marcus, additional

Published
2021
Full Text
View/download PDF

20. Improving Chemotherapy-Induced Peripheral Neuropathy in Patients with Breast or Colon Cancer after End of (Neo)adjuvant Therapy: Results from the Observational Study STEFANO

Author

Zaiss, Matthias, Uhlig, Jens, Zahn, Mark-Oliver, Decker, Thomas, Lehmann, Helmar C., Harde, Johanna, Hogrefe, Cathrin, Vannier, Corinne, Marschner, Norbert, Zaiss, Matthias, Uhlig, Jens, Zahn, Mark-Oliver, Decker, Thomas, Lehmann, Helmar C., Harde, Johanna, Hogrefe, Cathrin, Vannier, Corinne, and Marschner, Norbert

Abstract

Introduction: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect persisting after completion of neurotoxic chemotherapies. This observational study was designed to evaluate the effectiveness of the dietary supplement OnLife (R) (patented mixture of specific fatty acids and palmitoylethanolamide) in improving symptoms of CIPN in breast and colon cancer patients. Methods: Improvement of CIPN was evaluated in adult patients, previously treated with (neo)adjuvant paclitaxel- (breast cancer) or oxaliplatin-based (colon cancer) therapies, receiving OnLife (R) for 3 months after completion of chemotherapy. The primary endpoint was to compare the severity of peripheral sensory neuropathy (PSN) and peripheral motor neuropathy (PMN) before and at the end of OnLife (R) treatment. Secondary endpoints included the assessment of patient-reported quality of life and CIPN symptoms as assessed by questionnaires. Results: 146 patients (n = 75 breast cancer patients and n = 71 colon cancer patients) qualified for analysis; 31.1% and 37.5% of breast cancer patients had an improvement of PSN and PMN, respectively. In colon cancer patients, PSN and PMN improved in 16.9% and 20.0% of patients, respectively. According to patient-reported outcomes, 45.9% and 37.5% of patients with paclitaxel-induced PSN and PMN, and 23.9% and 22.0% of patients with oxaliplatin-induced PSN and PMN experienced a reduction of CIPN symptoms, respectively. Conclusion: OnLife (R) treatment confirmed to be beneficial in reducing CIPN severity and in limiting the progression of neuropathy, more markedly in paclitaxel-treated patients and also in patients with oxaliplatin-induced CIPN.

Published
2021

26. Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms : Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 1 mit Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms

Author

Wöckel, Achim, Festl, Jasmin, Stüber, Tanja, Brust, Katharina, Stangl, Stephanie, Heuschmann, Peter Ulrich, Albert, Ute Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kühn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, König, Klaus, Hahne, Andrea, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lüftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rüdiger, Hahn, Markus, Hanf, Volker, Müller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hölzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten Michael, Gerber , Bernd, Tesch, Hans, Hirsmüller, Susanne, Sinn, Hans-Peter, Dunst, Jürgen, Münstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk T., Beckmann, Matthias Wilhelm, Blohmer, Jens-Uwe, Fasching, Peter Andreas, Lux, Michael Patrick, Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Köbrunner, Sylvia H., Huober, Jens, Hübner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lück, Hans-Jürgen, Minckwitz, Gunter von, Möbus, Volker, Müller, Volkmar, Nöthlings, Ute, Schmidt, Marcus, Schmutzler, Rita Katharina, Schneeweiss, Andreas, Schütz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Bücker, Arno, and Krockenberger, Mathias

Subjects
ddc:610
Abstract

Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure. Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease. Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren. Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden. Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.

Published
2018

27. Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor–Positive Metastatic Breast Cancer

Author

Schmid, Peter, primary, Zaiss, Matthias, additional, Harper-Wynne, Catherine, additional, Ferreira, Marta, additional, Dubey, Sidharth, additional, Chan, Stephen, additional, Makris, Andreas, additional, Nemsadze, Gia, additional, Brunt, Adrian M., additional, Kuemmel, Sherko, additional, Ruiz, Isabel, additional, Perelló, Antonia, additional, Kendall, Anne, additional, Brown, Janet, additional, Kristeleit, Hartmut, additional, Conibear, John, additional, Saura, Cristina, additional, Grenier, Julien, additional, Máhr, Károly, additional, Schenker, Michael, additional, Sohn, Joohyuk, additional, Lee, Keun Seok, additional, Shepherd, Christopher J., additional, Oelmann, Elisabeth, additional, Sarker, Shah-Jalal, additional, Prendergast, Aaron, additional, Marosics, Patricia, additional, Moosa, Atiyyah, additional, Lawrence, Cheryl, additional, Coetzee, Carike, additional, Mousa, Kelly, additional, and Cortés, Javier, additional

Published
2019
Full Text
View/download PDF

30. Interdisziplinäre Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms : Leitlinie der DGGG und DKG (S3-Level, AWMF-Registernummer 032/045OL, Dezember 2017) – Teil 2 mit Empfehlungen zur Therapie des primären, rezidivierten und fortgeschrittenen Mammakarzinoms

Author

Wöckel, Achim, Festl, Jasmin, Stüber, Tanja, Brust, Katharina, Krockenberger, Mathias, Heuschmann, Peter U, Jírů-Hillmann, Steffi, Albert, Ute-Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kühn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, König, Klaus, Hahne, Andrea, Baumgartner, Traudl, Kreipe, Hans H, Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lüftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rüdiger, Hahn, Markus, Hanf, Volker, Müller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hölzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten, Gerber, Bernd, Tesch, Hans, Hirsmüller, Susanne, Sinn, Hans-Peter, Dunst, Jürgen, Münstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk, Beckmann, Matthias W, Blohmer, Jens, Fasching, Peter, Lux, Michael P, Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Köbrunner, Sylvia, Huober, Jens, Hübner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lück, Hans-Jürgen, von Minckwitz, Gunter, Möbus, Volker, Müller, Volkmar, Nöthlings, Ute, Schmidt, Marcus, Schmutzler, Rita, Schneeweiss, Andreas, Schütz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Bücker, Arno, Buck, Andreas, and Stangl, Stephanie

Subjects
Medizin
Published
2018

31. Prophylaxis of chemotherapy-induced neutropenia and febrile neutropenia with lipegfilgrastim in 2489 cancer patients: final results from the non-interventional study NADIR

Author

Fietz, Thomas, primary, Lück, Andreas, additional, Schulz, Holger, additional, Harde, Johanna, additional, Losem, Christoph, additional, Grebhardt, Sina, additional, Wolff, Thomas, additional, Potthoff, Karin, additional, Müller, Udo, additional, Zaiss, Matthias, additional, and Kurbacher, Christian Martin, additional

Published
2019
Full Text
View/download PDF

32. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

Author

Wöckel, Achim, additional, Festl, Jasmin, additional, Stüber, Tanja, additional, Brust, Katharina, additional, Krockenberger, Mathias, additional, Heuschmann, Peter, additional, Jírů-Hillmann, Steffi, additional, Albert, Ute-Susann, additional, Budach, Wilfried, additional, Follmann, Markus, additional, Janni, Wolfgang, additional, Kopp, Ina, additional, Kreienberg, Rolf, additional, Kühn, Thorsten, additional, Langer, Thomas, additional, Nothacker, Monika, additional, Scharl, Anton, additional, Schreer, Ingrid, additional, Link, Hartmut, additional, Engel, Jutta, additional, Fehm, Tanja, additional, Weis, Joachim, additional, Welt, Anja, additional, Steckelberg, Anke, additional, Feyer, Petra, additional, König, Klaus, additional, Hahne, Andrea, additional, Baumgartner, Traudl, additional, Kreipe, Hans, additional, Knoefel, Wolfram, additional, Denkinger, Michael, additional, Brucker, Sara, additional, Lüftner, Diana, additional, Kubisch, Christian, additional, Gerlach, Christina, additional, Lebeau, Annette, additional, Siedentopf, Friederike, additional, Petersen, Cordula, additional, Bartsch, Hans, additional, Schulz-Wendtland, Rüdiger, additional, Hahn, Markus, additional, Hanf, Volker, additional, Müller-Schimpfle, Markus, additional, Henscher, Ulla, additional, Roncarati, Renza, additional, Katalinic, Alexander, additional, Heitmann, Christoph, additional, Honegger, Christoph, additional, Paradies, Kerstin, additional, Bjelic-Radisic, Vesna, additional, Degenhardt, Friedrich, additional, Wenz, Frederik, additional, Rick, Oliver, additional, Hölzel, Dieter, additional, Zaiss, Matthias, additional, Kemper, Gudrun, additional, Budach, Volker, additional, Denkert, Carsten, additional, Gerber, Bernd, additional, Tesch, Hans, additional, Hirsmüller, Susanne, additional, Sinn, Hans-Peter, additional, Dunst, Jürgen, additional, Münstedt, Karsten, additional, Bick, Ulrich, additional, Fallenberg, Eva, additional, Tholen, Reina, additional, Hung, Roswita, additional, Baumann, Freerk, additional, Beckmann, Matthias, additional, Blohmer, Jens, additional, Fasching, Peter, additional, Lux, Michael, additional, Harbeck, Nadia, additional, Hadji, Peyman, additional, Hauner, Hans, additional, Heywang-Köbrunner, Sylvia, additional, Huober, Jens, additional, Hübner, Jutta, additional, Jackisch, Christian, additional, Loibl, Sibylle, additional, Lück, Hans-Jürgen, additional, von Minckwitz, Gunter, additional, Möbus, Volker, additional, Müller, Volkmar, additional, Nöthlings, Ute, additional, Schmidt, Marcus, additional, Schmutzler, Rita, additional, Schneeweiss, Andreas, additional, Schütz, Florian, additional, Stickeler, Elmar, additional, Thomssen, Christoph, additional, Untch, Michael, additional, Wesselmann, Simone, additional, Bücker, Arno, additional, Buck, Andreas, additional, and Stangl, Stephanie, additional

Published
2018
Full Text
View/download PDF

33. Impact of performance status and transfusion dependency on outcome of patients with myelodysplastic syndrome, acute myeloid leukemia and chronic myelomonocytic leukemia treated with azacitidine (PIAZA study)

Author

Wehmeyer, Jürgen, primary, Zaiss, Matthias, additional, Losem, Christoph, additional, Schmitz, Stephan, additional, Niemeier, Beate, additional, Harde, Johanna, additional, Hannig, Carla Verena, additional, Harich, Hanns-Detlev, additional, Müller, Judith, additional, Klausmann, Martine, additional, Tessen, Hans Werner, additional, and Potthoff, Karin, additional

Published
2018
Full Text
View/download PDF

34. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) – Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer

Author

Wöckel, Achim, additional, Festl, Jasmin, additional, Stüber, Tanja, additional, Brust, Katharina, additional, Stangl, Stephanie, additional, Heuschmann, Peter, additional, Albert, Ute-Susann, additional, Budach, Wilfried, additional, Follmann, Markus, additional, Janni, Wolfgang, additional, Kopp, Ina, additional, Kreienberg, Rolf, additional, Kühn, Thorsten, additional, Langer, Thomas, additional, Nothacker, Monika, additional, Scharl, Anton, additional, Schreer, Ingrid, additional, Link, Hartmut, additional, Engel, Jutta, additional, Fehm, Tanja, additional, Weis, Joachim, additional, Welt, Anja, additional, Steckelberg, Anke, additional, Feyer, Petra, additional, König, Klaus, additional, Hahne, Andrea, additional, Kreipe, Hans, additional, Knoefel, Wolfram, additional, Denkinger, Michael, additional, Brucker, Sara, additional, Lüftner, Diana, additional, Kubisch, Christian, additional, Gerlach, Christina, additional, Lebeau, Annette, additional, Siedentopf, Friederike, additional, Petersen, Cordula, additional, Bartsch, Hans, additional, Schulz-Wendtland, Rüdiger, additional, Hahn, Markus, additional, Hanf, Volker, additional, Müller-Schimpfle, Markus, additional, Henscher, Ulla, additional, Roncarati, Renza, additional, Katalinic, Alexander, additional, Heitmann, Christoph, additional, Honegger, Christoph, additional, Paradies, Kerstin, additional, Bjelic-Radisic, Vesna, additional, Degenhardt, Friedrich, additional, Wenz, Frederik, additional, Rick, Oliver, additional, Hölzel, Dieter, additional, Zaiss, Matthias, additional, Kemper, Gudrun, additional, Budach, Volker, additional, Denkert, Carsten, additional, Gerber, Bernd, additional, Tesch, Hans, additional, Hirsmüller, Susanne, additional, Sinn, Hans-Peter, additional, Dunst, Jürgen, additional, Münstedt, Karsten, additional, Bick, Ulrich, additional, Fallenberg, Eva, additional, Tholen, Reina, additional, Hung, Roswita, additional, Baumann, Freerk, additional, Beckmann, Matthias, additional, Blohmer, Jens, additional, Fasching, Peter, additional, Lux, Michael, additional, Harbeck, Nadia, additional, Hadji, Peyman, additional, Hauner, Hans, additional, Heywang-Köbrunner, Sylvia, additional, Huober, Jens, additional, Hübner, Jutta, additional, Jackisch, Christian, additional, Loibl, Sibylle, additional, Lück, Hans-Jürgen, additional, von Minckwitz, Gunter, additional, Möbus, Volker, additional, Müller, Volkmar, additional, Nöthlings, Ute, additional, Schmidt, Marcus, additional, Schmutzler, Rita, additional, Schneeweiss, Andreas, additional, Schütz, Florian, additional, Stickeler, Elmar, additional, Thomssen, Christoph, additional, Untch, Michael, additional, Wesselmann, Simone, additional, Bücker, Arno, additional, and Krockenberger, Mathias, additional

Published
2018
Full Text
View/download PDF

35. Palbociclib in Combination with either Aromatase Inhibitors or Fulvestrant for Patients with Advanced HR+/HER2− Breast Cancer in Germany: Final Results of the Phase 2 Multicohort INGE-B Trial.

Author

Welslau, Manfred, Potthoff, Karin, Zaiss, Matthias, Müller, Lothar, Brucker, Cosima, Salat, Christoph, Untch, Michael, Meiler, Johannes, Lüftner, Diana, Welt, Anja, Dörfel, Steffen, Hagen, Volker, Stein, Alexander, Liersch, Rüdiger, Kuhn, Thomas, Siebenbach, Hans Ulrich, Bing, Gerlinde, Vannier, Corinne, Marschner, Norbert, and Gratzke, Katja

Subjects
*FULVESTRANT, *HORMONE therapy, *AROMATASE inhibitors, *OVERALL survival, *PROGRESSION-free survival
Abstract

Introduction: The INGE-B trial (NCT02894398) aimed to confirm the efficacy and safety data from the PALOMA trials for patients treated first line (1L) with palbociclib (PAL) and letrozole or 1L and later line with PAL and fulvestrant. In addition, so far lacking evidence for efficacy and safety on the combination of PAL with anastrozole, exemestane (1L), or letrozole (later line) was investigated. Methods: The prospective, multicenter, multicohort phase 2 trial INGE-B enrolled adult patients with locally advanced, inoperable, or metastatic HR+/HER2− breast cancer in Germany. The primary endpoint was the clinical benefit rate (CBR) in patients with measurable disease according to RECIST v1.1. Secondary endpoints were overall response rate, progression-free survival (PFS), overall survival (OS), safety, and quality of life. Data were analyzed with descriptive statistics. Results: Between 2016 and 2018, 388 patients were enrolled at 64 German sites. Among patients with measurable disease treated with PAL in 1L (n = 157), the CBR was 63.7% (100/157). Among all patients treated with PAL 1L (n = 219), PFS was 20.1 months (95% CI 14.6–24.0), and OS was 40.9 months (95% CI 35.1–49.2). The most common grade 3/4 adverse event was neutropenia (33.4% n = 77). There were no treatment-related deaths. Conclusion: The INGE-B trial demonstrated good efficacy and tolerability of PAL with letrozole (1L) or fulvestrant (first and later line) in accordance with the PALOMA trials. In addition, the so far lacking proof of efficacy and safety of PAL in combination with anastrozole or exemestane in 1L and with letrozole in later line was provided by INGE-B. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

36. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer

Author

Woeckel, Achim, Festl, Jasmin, Stueber, Tanja, Brust, Katharina, Stangl, Stephanie, Heuschmann, Peter U., Albert, Ute-Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kuehn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, Koenig, Klaus, Hahne, Andrea, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lueftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Ruediger, Hahn, Markus, Hanf, Volker, Mueller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hoelzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten, Gerber, Bernd, Tesch, Hans, Hirsmueller, Susanne, Sinn, Hans-Peter, Dunst, Juergen, Muenstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk, Beckman, Matthias W., Blohmer, Jens, Fasching, Peter A., Lux, Michael P., Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Koebrunner, Sylvia, Huober, Jens, Huebner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lueck, Hans-Juergen, von Minckwitz, Gunter, Moebus, Volker, Mueller, Volkmar, Noethlings, Ute, Schmidt, Marcus, Schmutzler, Rita, Schneeweiss, Andreas, Schuetz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Buecker, Arno, Krockenberger, Mathias, Woeckel, Achim, Festl, Jasmin, Stueber, Tanja, Brust, Katharina, Stangl, Stephanie, Heuschmann, Peter U., Albert, Ute-Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kuehn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, Koenig, Klaus, Hahne, Andrea, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lueftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Ruediger, Hahn, Markus, Hanf, Volker, Mueller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hoelzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten, Gerber, Bernd, Tesch, Hans, Hirsmueller, Susanne, Sinn, Hans-Peter, Dunst, Juergen, Muenstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk, Beckman, Matthias W., Blohmer, Jens, Fasching, Peter A., Lux, Michael P., Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Koebrunner, Sylvia, Huober, Jens, Huebner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lueck, Hans-Juergen, von Minckwitz, Gunter, Moebus, Volker, Mueller, Volkmar, Noethlings, Ute, Schmidt, Marcus, Schmutzler, Rita, Schneeweiss, Andreas, Schuetz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Buecker, Arno, and Krockenberger, Mathias

Abstract

Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. Methods The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure. Recommendations Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease.

Published
2018

37. Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer

Author

Woeckel, Achim, Festl, Jasmin, Stueber, Tanja, Brust, Katharina, Krockenberger, Mathias, Heuschmann, Peter U., Jiru-Hillmann, Steffi, Albert, Ute-Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kuehn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, Koenig, Klaus, Hahne, Andrea, Baumgartner, Traudl, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lueftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rudiger, Hahn, Markus, Hanf, Volker, Mueller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hoelzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten, Gerber, Bernd, Tesch, Hans, Hirsmueller, Susanne, Sinn, Hans-Peter, Dunst, Juergen, Muenstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk, Beckmann, MatthiasW., Blohmer, Jens, Fasching, Peter, Lux, Michael P., Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Koebrunner, Sylvia, Huober, Jens, Huebner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lueck, Hans-Juergen, von Minckwitz, Gunter, Moebus, Volker, Mueller, Volkmar, Noethlings, Ute, Schmidt, Marcus, Schmutzler, Rita, Schneeweiss, Andreas, Schuetz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Buecker, Arno, Buck, Andreas, Stangl, Stephanie, Woeckel, Achim, Festl, Jasmin, Stueber, Tanja, Brust, Katharina, Krockenberger, Mathias, Heuschmann, Peter U., Jiru-Hillmann, Steffi, Albert, Ute-Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kuehn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, Koenig, Klaus, Hahne, Andrea, Baumgartner, Traudl, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lueftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rudiger, Hahn, Markus, Hanf, Volker, Mueller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hoelzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten, Gerber, Bernd, Tesch, Hans, Hirsmueller, Susanne, Sinn, Hans-Peter, Dunst, Juergen, Muenstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk, Beckmann, MatthiasW., Blohmer, Jens, Fasching, Peter, Lux, Michael P., Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Koebrunner, Sylvia, Huober, Jens, Huebner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lueck, Hans-Juergen, von Minckwitz, Gunter, Moebus, Volker, Mueller, Volkmar, Noethlings, Ute, Schmidt, Marcus, Schmutzler, Rita, Schneeweiss, Andreas, Schuetz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Buecker, Arno, Buck, Andreas, and Stangl, Stephanie

Abstract

Purpose The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. Method The process of updating the S3 guideline published in 2012 was based on the adaptation of identified source guidelines. They were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and with the results of a systematic search of literature databases followed by the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point and used them to develop suggestions for recommendations and statements, which were then modified and graded in a structured consensus process procedure. Recommendations Part 2 of this short version of the guideline presents recommendations for the therapy of primary, recurrent and metastatic breast cancer. Loco-regional therapies are de-escalated in the current guideline. In addition to reducing the safety margins for surgical procedures, the guideline also recommends reducing the radicality of axillary surgery. The choice and extent of systemic therapy depends on the respective tumor biology. New substances are becoming available, particularly to treat metastatic breast cancer.

Published
2018

38. Interdisciplinary screening, diagnosis, therapy and follow-up of breast cancer : guideline of the DGGG and the DKG (S3-level, AWMF registry number 032/045OL, December 2017) – part 1 with recommendations for the screening, diagnosis and therapy of breast cancer

Author

Wöckel, Achim, Festl, Jasmin, Stüber, Tanja, Brust, Katharina, Stangl, Stephanie, Heuschmann, Peter Ulrich, Albert, Ute Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kühn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, König, Klaus, Hahne, Andrea, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lüftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rüdiger, Hahn, Markus, Hanf, Volker, Müller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hölzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten Michael, Gerber, Bernd, Tesch, Hans, Hirsmüller, Susanne, Sinn, Hans-Peter, Dunst, Jürgen, Münstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk T., Beckmann, Matthias Wilhelm, Blohmer, Jens-Uwe, Fasching, Peter Andreas, Lux, Michael Patrick, Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Köbrunner, Sylvia H., Huober, Jens, Hübner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lück, Hans-Jürgen, Minckwitz, Gunter von, Möbus, Volker, Müller, Volkmar, Nöthlings, Ute, Schmidt, Marcus, Schmutzler, Rita Katharina, Schneeweiss, Andreas, Schütz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Bücker, Arno, Krockenberger, Mathias Heinric, Wöckel, Achim, Festl, Jasmin, Stüber, Tanja, Brust, Katharina, Stangl, Stephanie, Heuschmann, Peter Ulrich, Albert, Ute Susann, Budach, Wilfried, Follmann, Markus, Janni, Wolfgang, Kopp, Ina, Kreienberg, Rolf, Kühn, Thorsten, Langer, Thomas, Nothacker, Monika, Scharl, Anton, Schreer, Ingrid, Link, Hartmut, Engel, Jutta, Fehm, Tanja, Weis, Joachim, Welt, Anja, Steckelberg, Anke, Feyer, Petra, König, Klaus, Hahne, Andrea, Kreipe, Hans H., Knoefel, Wolfram Trudo, Denkinger, Michael, Brucker, Sara, Lüftner, Diana, Kubisch, Christian, Gerlach, Christina, Lebeau, Annette, Siedentopf, Friederike, Petersen, Cordula, Bartsch, Hans Helge, Schulz-Wendtland, Rüdiger, Hahn, Markus, Hanf, Volker, Müller-Schimpfle, Markus, Henscher, Ulla, Roncarati, Renza, Katalinic, Alexander, Heitmann, Christoph, Honegger, Christoph, Paradies, Kerstin, Bjelic-Radisic, Vesna, Degenhardt, Friedrich, Wenz, Frederik, Rick, Oliver, Hölzel, Dieter, Zaiss, Matthias, Kemper, Gudrun, Budach, Volker, Denkert, Carsten Michael, Gerber, Bernd, Tesch, Hans, Hirsmüller, Susanne, Sinn, Hans-Peter, Dunst, Jürgen, Münstedt, Karsten, Bick, Ulrich, Fallenberg, Eva, Tholen, Reina, Hung, Roswita, Baumann, Freerk T., Beckmann, Matthias Wilhelm, Blohmer, Jens-Uwe, Fasching, Peter Andreas, Lux, Michael Patrick, Harbeck, Nadia, Hadji, Peyman, Hauner, Hans, Heywang-Köbrunner, Sylvia H., Huober, Jens, Hübner, Jutta, Jackisch, Christian, Loibl, Sibylle, Lück, Hans-Jürgen, Minckwitz, Gunter von, Möbus, Volker, Müller, Volkmar, Nöthlings, Ute, Schmidt, Marcus, Schmutzler, Rita Katharina, Schneeweiss, Andreas, Schütz, Florian, Stickeler, Elmar, Thomssen, Christoph, Untch, Michael, Wesselmann, Simone, Bücker, Arno, and Krockenberger, Mathias Heinric

Abstract

Purpose: The aim of this official guideline coordinated and published by the German Society for Gynecology and Obstetrics (DGGG) and the German Cancer Society (DKG) was to optimize the screening, diagnosis, therapy and follow-up care of breast cancer. Methods: The process of updating the S3 guideline dating from 2012 was based on the adaptation of identified source guidelines which were combined with reviews of evidence compiled using PICO (Patients/Interventions/Control/Outcome) questions and the results of a systematic search of literature databases and the selection and evaluation of the identified literature. The interdisciplinary working groups took the identified materials as their starting point to develop recommendations and statements which were modified and graded in a structured consensus procedure. Recommendations: Part 1 of this short version of the guideline presents recommendations for the screening, diagnosis and follow-up care of breast cancer. The importance of mammography for screening is confirmed in this updated version of the guideline and forms the basis for all screening. In addition to the conventional methods used to diagnose breast cancer, computed tomography (CT) is recommended for staging in women with a higher risk of recurrence. The follow-up concept includes suggested intervals between physical, ultrasound and mammography examinations, additional high-tech diagnostic procedures, and the determination of tumor markers for the evaluation of metastatic disease., Ziele: Das Ziel dieser offiziellen Leitlinie, die von der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) und der Deutschen Krebsgesellschaft (DKG) publiziert und koordiniert wurde, ist es, die Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms zu optimieren. Methoden: Der Aktualisierungsprozess der S3-Leitlinie aus 2012 basierte zum einen auf der Adaptation identifizierter Quellleitlinien und zum anderen auf Evidenzübersichten, die nach Entwicklung von PICO-(Patients/Interventions/Control/Outcome-)Fragen, systematischer Recherche in Literaturdatenbanken sowie Selektion und Bewertung der gefundenen Literatur angefertigt wurden. In den interdisziplinären Arbeitsgruppen wurden auf dieser Grundlage Vorschläge für Empfehlungen und Statements erarbeitet, die im Rahmen von strukturierten Konsensusverfahren modifiziert und graduiert wurden. Empfehlungen: Der Teil 1 dieser Kurzversion der Leitlinie zeigt Empfehlungen zur Früherkennung, Diagnostik und Nachsorge des Mammakarzinoms: Der Stellenwert des Mammografie-Screenings wird in der aktualisierten Leitlinienversion bestätigt und bildet damit die Grundlage der Früherkennung. Neben den konventionellen Methoden der Karzinomdiagnostik wird die Computertomografie (CT) zum Staging bei höherem Rückfallrisiko empfohlen. Die Nachsorgekonzepte beinhalten Untersuchungsintervalle für die körperliche Untersuchung, Ultraschall und Mammografie, während weiterführende Gerätediagnostik und Tumormarkerbestimmungen bei der metastasierten Erkrankung Anwendung finden.

Published
2018

39. Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)

Author

Griesinger, Frank, Sebastian, Martin, Brueckl, Wolfgang M., Hummel, Horst-Dieter, Jaeschke, Bastian, Kern, Jens, Wesseler, Claas, Jänicke, Martina, Fleitz, Annette, Zacharias, Stefan, Hipper, Annette, Groth, Annika, Weichert, Wilko, Dörfel, Steffen, Petersen, Volker, Schröder, Jan, Wilke, Jochen, Eberhardt, Wilfried E.E., Thomas, Michael, Ababei, Juliana, Alt, Jürgen, Ammon, Andreas, Anhuf, Jürgen, Azeh, Ivo, Bauer, Stefan, Behringer, Dirk, Berger, Winfried, Bernhardt, Christiane, Bertram, Mathias, Boesche, Michael, Bohnet, Sabine, Bruch, Harald-Robert, Brückl, Wolfgang, Burkhard-Meier, Ulrike, Christopoulos, Petros, Däßler, Klaus-Ulrich, de Wit, Maike, Dechow, Tobias, Depenbusch, Reinhard, Dietze, Lutz, Dommach, Markus, Dörfel, Steffen, Eberhardt, Wilfried, Elender, Corinna, Elsel, Wolfgang, Emde, Till-Oliver, Faehling, Martin, Fietz, Thomas, Fischer, Jürgen R., Flieger, Dimitri, Freidt, Anke, Freier, Werner, Frenzel, Christian, Fuchs, Florian, Fuchs, Roswitha, Gaska, Tobias, Gleiber, Wolfgang, Grah, Christian, Griesinger, Frank, Grohé, Christian, Groschek, Matthias, Güldenzoph, Björn, Günther, Andreas, Haas, Siegfried, Hackenthal, Matthias, Hagen, Volker, Hahn, Lars, Hannig Carla, Verena, Hansen, Richard, Harich, Hanns-Detlev, Heilmann, Monika, Heinrich, Kathrin, Hering-Schubert, Christiane, Heßling, Jörg, Hoffknecht, Petra, Hortig, Patricia, Hübner, Gerdt, Hummel, Horst-Dieter, Hutzschenreuter, Ulrich, Illmer, Thomas, Innig, Georg, Jaeschke, Bastian, Junghanß, Christian, Kaiser, Ulrich, Kamal, Haytham, Kambartel, Kato, Kern, Jens, Kimmich, Martin, Kingreen, Dorothea, Kirchen, Heinz, Klausmann, Martine, Klein, Ortwin, Kokowski, Konrad, Körber, Wolfgang, Kortsik, Cornelius, Koschel, Dirk, Krämer, Benoit, Krammer-Steiner, Beate, Laack, Eckart, Lamberti, Christof, Leistner, Rumo David, Losem, Christoph, Lück, Andreas, Maintz, Christoph, Martin, Kerstin, Medgenberg, Dirk, Metzenmacher, Martin, Meyer zum Büschenfelde, Christian, Meyn, Philipp, Moorahrend, Enno, Müller, Annette, Müller, Lothar, Neise, Michael, Nückel, Holger, Nusch, Arnd, Overbeck, Tobias, Pelz, Henning, Petersen, Volker, Peuser, Bettina, Plath, Margarete, Randerath, Winfried J., Rauh, Jacqueline, Reck, Martin, Reichert, Dietmar, Reinmuth, Niels, Reiser, Marcel, Repp, Roland, Reschke, Daniel, Rittmeyer, Achim, Rodemer, Yolanda, Sackmann, Sandra, Sadjadian, Parvis, Sandner, Reiner, Sauer, Annette, Schäfer, Harald, Schaudt, Christoph, Schlag, Rudolf, Schmidt, Burkhard, Schmitz, Stephan, Schröder, Jan, Schroeder, Michael, Schulze, Mathias, Schumann, Christian, Schütte, Wolfgang, Schwaiblmair, Martin, Schwindt Peter, Florian, Sebastian, Martin, Seese, Bernd, Seipelt, Gernot, Sorgenfrei, Thomas, Steiff, Johannes, Steiniger, Heike, Trarbach, Tanja, Tufman, Amanda, Uhlig, Jens, Vehling-Kaiser, Ursula, von der Heyde, Eyck, von Verschuer, Ulla, Waller, Cornelius, Wehler, Thomas, Weißenborn, Georg, Weißinger, Florian, Wermke, Martin, Wesseler, Claas, Wiegand, Jörg, Wilhelm, Stefan, Wilke, Jochen, Zahn, Mark-Oliver, Zaiss, Matthias, and Zeth, Matthias

Abstract

Patients with metastatic NSCLC (mNSCLC) treated with immune checkpoint inhibitors in clinical practice may often not meet the strict inclusion criteria of clinical trials. Our aim was to assess the trial eligibility of patients with mNSCLC treated with pembrolizumab monotherapy in real-world and to compare the outcome of “trial-ineligible” and “potentially trial-eligible” patients.

Published
2024
Full Text
View/download PDF

40. Phase III randomized sequential open-label study to evaluate the efficacy and safety of sorafenib followed by pazopanib versus pazopanib followed by sorafenib in the treatment of advanced/metastatic renal cell carcinoma (SWITCH-2 study).

Author

Gschwend, Juergen, primary, Beeker, Aart, additional, de Santis, Maria, additional, Brehmer, Bernhard, additional, Zaiss, Matthias R., additional, Schirrmacher-Memmel, Silke, additional, Von Verschuer, Ulla, additional, Bos, Monique M.E.M., additional, Pahernik, Sascha, additional, Grimm, Marc-Oliver, additional, Krause, Steffen, additional, and Retz, Margitta, additional

Published
2013
Full Text
View/download PDF

42. Expression and Function of Homing-Essential Molecules and Enhanced In Vivo Homing Ability of Human Peripheral Blood-Derived Hematopoietic Progenitor Cells after Stimulation with Stem Cell Factor

Author

Hart, Christina, primary, Drewel, Diana, additional, Mueller, Gunnar, additional, Grassinger, Jochen, additional, Zaiss, Matthias, additional, Kunz-Schughart, Leonia A., additional, Andreesen, Reinhard, additional, Reichle, Albrecht, additional, Holler, Ernst, additional, and Hennemann, Burkhard, additional

Published
2004
Full Text
View/download PDF

44. Head-to-head comparison of palbociclib and ribociclib in first-line treatment of HR-positive/HER2-negative metastatic breast cancer with real-world data from the OPAL registry.

Author

Thill M, Zahn MO, Welt A, Nusch A, Zaiss M, Engelken K, Kaltenecker G, Ringwald K, Gratzke K, Dille S, Kruggel L, Jänicke M, Schulz H, Hagen V, Fricker R, Stickeler E, Harbeck N, Wöckel A, and Decker T

Abstract

Cyclin-dependent kinase 4/6 inhibitors (CDKIs) in combination with endocrine therapy (ET) are the standard-of-care in the first-line treatment of HR-positive, HER2-negative metastatic breast cancer. In the absence of direct head-to-head trials comparing the efficacy and safety of the different CDKIs, the individual choice of treatment in everyday practice is complex. Inverse probability of treatment weighting was used to emulate a head-to-head comparison of palbociclib +ET (PALBO) and ribociclib +ET (RIBO) in patients recruited into the prospective, observational, multicenter registry platform OPAL (NCT03417115). Progression-free survival (PFS), overall survival (OS) and quality of life surveys were analyzed, also for subgroups stratified by treatment-free interval (TFI). A total of 623 patients with HR-positive, HER2-negative metastatic breast cancer received PALBO (n = 388) or RIBO (n = 235) in their first line of treatment. No difference between PALBO and RIBO was found for PFS (median 26.7 months [23.6, 30.7] vs. 27.0 months [21.1, 30.4], HR 1.01 [0.80, 1.27]) and OS (median 42.4 months [38.8, 50.3] vs. 49.3 months [36.9, NA], HR 0.96 [0.71, 1.28]). There was a trend for longer PFS and OS in patients with TFI <12 months receiving RIBO. Patients reported comparable side effects for both CDKIs. This head-to-head comparison revealed no difference in PFS and OS between PALBO and RIBO, however, a trend to longer PFS and OS with RIBO was observed in the subgroup of patients with TFI <12 months. Side effects experienced with PALBO and RIBO highlight the important toxicities to be addressed during treatment decision., (© 2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results